Biomarkers: What you need to know
Immuno-oncology has been the new hot cancer space for the last few years, with Opdivo and Keytruda dominating the landscape. Yet, the overwhelming success of these two drugs has also brought attention to an area of science that is still somewhat controversial: biomarkers.
Just two years ago, the use of biomarkers to determine specific patient populations for a treatment was considered informative, but not necessary. In that time, the landscape has shifted and biomarkers, as well as their corresponding diagnostics have started to prove their relevance.
Here's a look at what biomarkers are, how they are shaping the industry and the diagnostic tests that go hand-in-hand.
Sequencing of the human genome has shifted the development of diagnostics to include biomarker tests that are revolutionizing drug development. Read More >>
The role of biomarkers in immuno-oncology and other cancer treatments is becoming increasingly important and is driving investment into multiple industries, including liquid biopsies and diagnostics. Read More >>
A risk-averse approach to biomarkers opened the door for Merck's Keytruda to surpass Bristol-Myers' Opdivo in the highly important lung cancer market. Read More >>
Money is flooding into the space as dozens of companies work to develop reliable tests for cancer from a simple blood draw. Read More >>
Exosome Sciences is investigating a potential biomarker for a rare neurodegenerative disease that has plagued veterans and professional athletes. Read More >>
Follow Lisa LaMotta on Twitter